Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9755877rdf:typepubmed:Citationlld:pubmed
pubmed-article:9755877lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:9755877lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:9755877lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9755877lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:9755877lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:9755877lifeskim:mentionsumls-concept:C0332152lld:lifeskim
pubmed-article:9755877pubmed:issue1lld:pubmed
pubmed-article:9755877pubmed:dateCreated1998-10-16lld:pubmed
pubmed-article:9755877pubmed:abstractTextmAb hCTM01 binds a carcinoma-associated antigen, the MUC1 gene product. The antigen is also present in the circulation, and administration of 111In-labelled hCTM01 results in the formation of immune complexes with enhanced accumulation in the liver. To avoid the unwanted effect of circulating radioactive immune complexes, a strategy to remove the circulating antigen was investigated using a split-dosage schedule. Eleven patients suspected of having ovarian carcinoma were injected with 1 mg/kg unlabelled hCTM01, 1 h before receiving 0.1 mg/kg 111In-labelled hCTM01 (100 M Bq). The amount of radioactivity was determined in resected tumour tissue, various normal tissues and blood samples obtained at laparotomy 6 days postinjection (p.i.). In all patients, the circulating antigen decreased to its nadir after the unlabelled antibody infusion and immune complex formation was demonstrated. Uptake in tumour deposits 6 days p.i. was 11.1 times higher than in normal tissues (P < 0.0001) and 5.9 times higher than in blood (P < 0.0001). 111In activity in liver tissue was comparable to 111In uptake in tumour tissue, and considerably lower than previously reported in patients not pretreated with unlabelled antibody. The split-dosing strategy would appear to be advantageous for use of hCTM01 as a specific carrier for the delivery of cytotoxic agents to patients with ovarian cancer.lld:pubmed
pubmed-article:9755877pubmed:languageenglld:pubmed
pubmed-article:9755877pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9755877pubmed:citationSubsetIMlld:pubmed
pubmed-article:9755877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9755877pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9755877pubmed:statusMEDLINElld:pubmed
pubmed-article:9755877pubmed:monthSeplld:pubmed
pubmed-article:9755877pubmed:issn0340-7004lld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:SymondsE MEMlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:FrierMMlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:BakerT STSlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:RoosJ CJClld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:den...lld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:KenemansPPlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:PerkinsA CAClld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:van HofA CAClld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:VerheijenR...lld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:MolthoffC FCFlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:SopwithMMlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:WilhelmA JAJlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:PrinssenH MHMlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:DaviesQQlld:pubmed
pubmed-article:9755877pubmed:authorpubmed-author:BroadheadT...lld:pubmed
pubmed-article:9755877pubmed:issnTypePrintlld:pubmed
pubmed-article:9755877pubmed:volume47lld:pubmed
pubmed-article:9755877pubmed:ownerNLMlld:pubmed
pubmed-article:9755877pubmed:authorsCompleteYlld:pubmed
pubmed-article:9755877pubmed:pagination39-46lld:pubmed
pubmed-article:9755877pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:meshHeadingpubmed-meshheading:9755877-...lld:pubmed
pubmed-article:9755877pubmed:year1998lld:pubmed
pubmed-article:9755877pubmed:articleTitleBiodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01.lld:pubmed
pubmed-article:9755877pubmed:affiliationDepartment of Obstetrics and Gynaecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:9755877pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9755877lld:pubmed